SLNO Share Price | Soleno Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Soleno Therapeutics, Inc.?

Market Cap: As of Jun 18, Soleno Therapeutics, Inc. has a market capitalization of 3,910.57 million, which classifies it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Soleno Therapeutics reported net sales of 0.00 million and a net profit of -198.22 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 245.11 million and total assets of 330.97 million.

Q: What does Soleno Therapeutics, Inc. do?

Overview:Soleno Therapeutics, Inc. is a healthcare company that develops and commercializes neonatology devices and diagnostics, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -44 Million (Quarterly Results - Mar 2025) Market-cap: USD 3,910.57 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.03 Return on Equity: -82.85% Price to Book: 16.84Contact Details:Address: 1235 Radio Rd Ste 110, REDWOOD CITY CA: 94065-1217 Tel: 1 650 2138444 Fax: 1 302 6555049 Website: http://www.capnia.com

Q: Is Soleno Therapeutics, Inc. overvalued or undervalued?

As of 6 August 2025, the valuation grade for Soleno Therapeutics, Inc. has moved from does not qualify to risky, indicating a heightened level of concern regarding its financial health. The company appears to be overvalued given its negative performance metrics, including a P/E ratio of NA due to losses, a Price to Book Value of 16.38, and a troubling ROE of -82.85%. In comparison to its peers, Soleno's EV to EBITDA stands at -17.64, while Arcutis Biotherapeutics, Inc. and EyePoint Pharmaceuticals, Inc. have ratios of -24.8858 and -3.6610, respectively. This suggests that Soleno is not only underperforming relative to its industry but also faces significant challenges in generating positive returns. Notably, over the past year, Soleno's stock has returned 5.66%, significantly lagging behind the S&P 500's return of 17.14%, reinforcing the notion that the stock is overvalued in its current state.

Q: Is Soleno Therapeutics, Inc. technically bullish or bearish?

As of 19 September 2025, the technical trend for Soleno Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD is bearish, while the monthly MACD remains bullish, indicating mixed signals across time frames. The Bollinger Bands are mildly bearish on the weekly and bearish on the monthly, supporting the bearish stance. Moving averages show a mildly bullish signal on the daily, but this is overshadowed by the overall bearish indicators from the KST, Dow Theory, and OBV, all of which are mildly bearish on both weekly and monthly charts. In terms of performance, the stock has returned 21.78% year-to-date, outperforming the S&P 500's 13.31%, but has underperformed over the past month with a return of -18.07% compared to the S&P 500's 3.95%. Overall, the current technical stance is mildly bearish.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

594.6 k

Shareholding (Dec 2025)

FII

19.13%

Held by 119 FIIs

DII

21.53%

Held by 61 DIIs

Promoter

6.30%

How big is Soleno Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Soleno Therapeutics, Inc. has a market capitalization of $3.91 billion, with net sales of $0.00 million and a net profit of -$198.22 million over the last four quarters. The company reported shareholder's funds of $245.11 million and total assets of $330.97 million as of Dec 24.

View full answer

What does Soleno Therapeutics, Inc. do?

22-Jun-2025

Soleno Therapeutics, Inc. is a micro-cap healthcare company focused on developing and commercializing devices and diagnostics for neonatology. As of March 2025, it reported a net profit loss of $44 million and has a market cap of approximately $3.91 billion.

View full answer

Who are in the management team of Soleno Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Soleno Therapeutics, Inc. includes Dr. Ernest Mario as the Independent Chairman and Dr. Anish Bhatnagar as the President and CEO, along with Independent Directors Mr. William Harris, Ms. Gwen Melincoff, Mr. Andrew Sinclair, and Dr. Birgitte Volck.

View full answer

Is Soleno Therapeutics, Inc. overvalued or undervalued?

20-Sep-2025

As of August 6, 2025, Soleno Therapeutics, Inc. is rated as risky due to its overvaluation, negative performance metrics, and a stock return of 5.66% over the past year, significantly underperforming the S&P 500's 17.14% return.

View full answer

Is Soleno Therapeutics, Inc. technically bullish or bearish?

22-Sep-2025

As of September 19, 2025, Soleno Therapeutics, Inc. shows a mildly bearish trend with mixed signals from various indicators, despite a year-to-date return of 21.78% that outperforms the S&P 500.

View full answer

Compare Soleno Therapeutics, Inc. with Similar Stocks

EyePoint Pharmaceuticals, Inc.MacroGenics, Inc.Arcutis Biotherapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

With a growth in Net Sales of INF%, the company declared Outstanding results in Sep 25

The company has declared positive results in Jan 70 after 7 consecutive negative quarters
ROCE(HY) Highest at -20.66%
OPERATING PROFIT(Q) Highest at USD 23.22 MM
PRE-TAX PROFIT(Q) Highest at USD 26.63 MM

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,724 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.91

Return on Equity

-14.84%

Price to Book

3.48

Revenue and Profits:

Net Sales:

92 Million

(Quarterly Results - Dec 2025)

Net Profit:

43 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-36.22%

6 Months

-51.41%

1 Year

-37.5%

2 Years

-25.4%

3 Years

1233.62%

4 Years

612.35%

5 Years

54.77%

Soleno Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

151.03%

EBIT Growth (5y)

-193.58%

EBIT to Interest (avg)

-54.29

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.15

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.48

EV to EBIT

-15.13

EV to EBITDA

-15.50

EV to Capital Employed

27.47

EV to Sales

12.92

PEG Ratio

Dividend Yield

ROCE (Latest)

-181.53%

ROE (Latest)

-14.84%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 72 Schemes (53.04%)

Foreign Institutions

Held by 119 Foreign Institutions (19.13%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 176.61% vs -395.58% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "91.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "40.90",
          "val2": "-58.30",
          "chgp": "170.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "0.20",
          "chgp": "550.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "-0.30",
          "chgp": "-200.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "42.90",
          "val2": "-56.00",
          "chgp": "176.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "440.80%",
          "val2": "0.00%",
          "chgp": "44.08%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 111.65% vs -351.03% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "190.40",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "17.00",
          "val2": "-182.40",
          "chgp": "109.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.50",
          "val2": "0.20",
          "chgp": "2,650.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.50",
          "val2": "-3.20",
          "chgp": "-71.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "20.50",
          "val2": "-175.90",
          "chgp": "111.65%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "78.50%",
          "val2": "0.00%",
          "chgp": "7.85%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

91.70

0.00

Operating Profit (PBDIT) excl Other Income

40.90

-58.30

170.15%

Interest

1.30

0.20

550.00%

Exceptional Items

-0.90

-0.30

-200.00%

Consolidate Net Profit

42.90

-56.00

176.61%

Operating Profit Margin (Excl OI)

440.80%

0.00%

44.08%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 176.61% vs -395.58% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

190.40

0.00

Operating Profit (PBDIT) excl Other Income

17.00

-182.40

109.32%

Interest

5.50

0.20

2,650.00%

Exceptional Items

-5.50

-3.20

-71.88%

Consolidate Net Profit

20.50

-175.90

111.65%

Operating Profit Margin (Excl OI)

78.50%

0.00%

7.85%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 111.65% vs -351.03% in Dec 2024

All Annual Results

Company CV

About Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.

Company Coordinates

Company Details

1235 Radio Rd Ste 110 , REDWOOD CITY CA : 94065-1217

Tel: 1 650 2138444

http://www.capnia.com

Registrar Details